Syndax is a commercial-stage biopharmaceutical company that develops and commercializes innovative cancer therapies and treatments for serious hematologic and immunologic diseases. The company's marketed products include Revuforj (revumenib), a menin inhibitor approved for relapsed/refractory acute leukemias, and Niktimvo (axatilimab-csfr), a CSF-1R blocking antibody approved for chronic graft-versus-host disease, with a clinical pipeline exploring additional indications in myelofibrosis, idiopathic pulmonary fibrosis, and other disease areas. Syndax generates revenue directly from U.S. sales of Revuforj and through a 50/50 profit-share arrangement with Incyte for Niktimvo in the United States, while receiving tiered royalties on international sales; the company also monetizes royalty streams through financial agreements with third parties and retains milestone and royalty obligations to its licensors.